体检人群非酒精性脂肪性肝病与心血管疾病发病风险的关联性研究

doi:10.3969/j.issn.1006-5253.2022.02.001

Abstract
Figure/Table
References (0)
Related Citation (3)

Download: PDF (931 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the prevalence of nonalcoholic fatty liver disease (NAFLD) among physical examination population in Xianyang City, and to analyze the relationship between NAFLD and risk of cardiovascular diseases, so as to provide basis and suggestions for the prevention of cardiovascular diseases in population with NAFLD.Methods Totally 15 766 subjects were selected from the Health Management Center of Xianyang Central Hospital in 2019. Blood pressure, height, weight, blood glucose, blood lipid and other indices were collected to diagnose fatty liver by ultrasound. The 10 year risk assessment method of atherosclerotic cardiovascular disease (ASCVD) provided by the Guidelines for the Prevention of Cardiovascular Diseases in China (2017) was used to estimate the risk of ASCVD in the examined population in the next 10 years. Multiple logistic regression analysis was used to analyze the relationship between NAFLD and the risk of ASCVD in the next 10 years.Results The overall prevalence of NAFLD was 38.3%, men had a higher prevalence than women (43.8% vs 29.6%) , and the prevalence of NAFLD was different in age groups (χ²=272.57, P<0.001). The risk of ASCVD in the next 10 years showed that the extremely high-risk was 2.0%, the high risk was 14.3%, the intermediate risk was 13.4% and the low risk was 70.3%. After controlling for age, sex, diabetes, hypertension, overweight or obesity, dyslipidemia and smoking confounding factors, compared with non NAFLD population, the risk of ASCVD in NAFLD population in the next 10 years increased by 31% (or = 1.31, 95%ci: 1.12~1.52), and the or values in male and female population were 1.35 (95%ci:1.12~1.61) and 1.20 (95%ci:0.86~1.68) respectively. The relationship between NAFLD and the risk of cardiovascular disease remained unchanged after excluding extremely high-risk groups. Conclusion The prevalence of NAFLD is high among the physical examination population in Xianyang city. NAFLD can increase the risk of ASCVD in the next 10 years. It is suggested that the risk assessment of cardiovascular disease should be carried out among the physical examination population of NAFLD, especially men, in order to slow down the progress of cardiovascular disease control.

Key words： non-alcoholic fatty liver disease atherosclerotic cardiovascular disease risk assessment physical examination population

Received: 25 January 2022

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Shui Mingming
	Shi Ming
	Li Yanping
	Zhang Chen
	Dang Shaonong

Cite this article:

Shui Mingming,Shi Ming,Li Yanping, et al. Association between non-alcoholic fatty liver disease and risk of cardiovascular diseases in physical examination population[J]. journal1, 2022, 29(2): 81-86.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2022.02.001 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2022/V29/I2/81

［1］BISACCIA G, RICCI F, MANTINI C, et al. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes［J］. SAGE Open Med, 2020, 8:2050312120933804. DOI:10.1177/2050312120933804.
［2］WU S Q, WU F Q, DING Y Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis［J］. Sci Rep, 2016, 6:33386. DOI:10.1038/srep33386.
［3］EKSTEDT M, HAGSTRM H, NASR P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up［J］. Hepatology, 2015, 61(5):1547-1554. DOI:10.1002/hep.27368.
［4］国家“十五”攻关“冠心病、脑卒中综合危险度评估及干预方案的研究”课题组．国人缺血性心血管病发病危险的评估方法及简易评估工具的开发研究［J］．中华心血管病杂志，2003，31(12)：893-901．DOI:10.3760/j:issn:0253-3758.2003.12.005.
［5］杨春军，宋颖．心血管疾病危险因素分析及评估工具的研究进展［J］．中国老年保健医学，2021，19(4)：126-129．DOI:10.3969/j.issn.1672-2671.2021.04.037.
［6］中国心血管病预防指南写作组，中华心血管病杂志编辑委员会．中国心血管病预防指南:2017［J］．中华心血管病杂志，2018，46(1)：10-25．DOI:10.3760/cma.j.issn.0253-3758.2018.01.004.
［7］中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南:2018更新版［J］．中华肝脏病杂志，2018，26(3)：195-203．DOI:10.3760/cma.j.issn.1007-3418.2018.03.008.
［8］ZHOU Y J, LI Y Y, NIE Y Q, et al. Prevalence of fatty liver disease and its risk factors in the population of South China［J］. World J Gastroenterol, 2007, 13(47):6419-6424. DOI:10.3748/wjg.v13.i47.6419.
［9］LIN S L, XIAN Y J, LIU Y, et al. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China［J］. Medicine, 2018, 97(9):e0021. DOI:10.1097/MD.0000000000010021.
［10］CHEN C H, HUANG M H, YANG J C, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: Metabolic significance of nonalcoholic fatty liver disease in nonobese adults［J］. J Clin Gastroenterol, 2006, 40(8):745-752. DOI:10.1097/00004836-200609000-00016.

［11］ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement［J］. J Hepatol, 2020, 73(1):202-209. DOI:10.1016/j.jhep.2020.03.039.
［12］刘晓芬，赵清水，何莹，等．2017年北京市房山区35岁及以上居民心血管病相关危险因素分布及风险评估［J］．首都公共卫生，2019，13(3)：130-133．DOI:10.16760/j.cnki.sdggws.2019.03.004.
［13］白宁静，黄志辉．某地区铁路职工ASCVD总体发病危险评估调查分析［J］．铁路节能环保与安全卫生，2020，10(2)：50-53．DOI:10.16374/j.cnki.issn2095-1671.2020.0024.
［14］陈轶英，朱丽萍，颜玮，等．江西省18岁及以上常住居民心血管病发病风险评估［J］．中国慢性病预防与控制，2021，29(9)：654-659．DOI:10.16386/j.cjpccd.issn.1004-6194.2021.09.004.
［15］YE Q, ZOU B Y, YEO Y H, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis［J］. Lancet Gastroenterol Hepatol, 2020, 5(8):739-752. DOI:10.1016/S2468-1253(20)30077-7.
［16］FOTBOLCU H, ZORLU E. Nonalcoholic fatty liver disease as a multisystemic disease［J］. World J Gastroenterol, 2016, 22(16):4079-4090. DOI:10.3748/wjg.v22.i16.4079.
［17］STAHL E P, DHINDSA D S, LEE S K, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review［J］. J Am Coll Cardiol, 2019, 73(8):948-963. DOI:10.1016/j.jacc.2018.11.050.
［18］JANSSEN A, GROBBEE D E, DENDALE P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease［J］. Eur J Prev Cardiol, 2020, 27(10):1059-1063. DOI:10.1177/2047487319891783.
［19］TAMAKI N, KUROSAKI M, TAKAHASHI Y, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease［J］. J Gastroenterol Hepatol, 2021, 36(10):2960-2966. DOI:10.1111/jgh.15589.
［20］KASPER P, MARTIN A, LANG S, et al. NAFLD and cardiovascular diseases: A clinical review［J］. Clin Res Cardiol, 2021, 110(7):921-937. DOI:10.1007/s00392-020-01709-7.